JAK2 and acquired polycythemia vera: Ruxolitinib, a JAK1/JAK2 inhibitor, represents a clinical standard of care for patients with intermediate or high-risk MF [6], and has also been approved for patients with PV that are resistant or intolerant to hydroxyurea [7].